TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Gary Gordon purchased 10,000 shares of TriSalus Life Sciences stock in a transaction dated Tuesday, November 17th. The shares were purchased at an average cost of $2.20 per share, for a total transaction of $22,000.00. Following the completion of the transaction, the director owned 82,510 shares of the company’s stock, valued at approximately $181,522. This represents a 13.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
TriSalus Life Sciences Trading Down 11.4%
Shares of TLSI stock opened at $2.17 on Friday. TriSalus Life Sciences, Inc. has a 12-month low of $2.16 and a 12-month high of $7.95. The company has a debt-to-equity ratio of 47.60, a current ratio of 4.22 and a quick ratio of 3.86. The firm has a fifty day moving average of $3.85 and a 200-day moving average of $4.24.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million. Sell-side analysts predict that TriSalus Life Sciences, Inc. will post -0.62 EPS for the current fiscal year.
Institutional Investors Weigh In On TriSalus Life Sciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC lifted its position in TriSalus Life Sciences by 29.3% in the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock valued at $29,814,000 after acquiring an additional 1,485,664 shares in the last quarter. BlackRock Inc. bought a new position in TriSalus Life Sciences during the 2nd quarter worth about $12,099,000. Nantahala Capital Management LLC bought a new position in TriSalus Life Sciences during the 2nd quarter worth about $4,550,000. State Street Corp increased its holdings in TriSalus Life Sciences by 9.5% during the 3rd quarter. State Street Corp now owns 668,897 shares of the company’s stock worth $2,883,000 after purchasing an additional 57,934 shares in the last quarter. Finally, White Pine Capital LLC bought a new position in TriSalus Life Sciences during the 3rd quarter worth about $2,143,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have issued reports on the company. HC Wainwright decreased their target price on TriSalus Life Sciences from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Stifel Nicolaus set a $12.00 price target on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Citigroup reiterated a “buy” rating on shares of TriSalus Life Sciences in a report on Tuesday, November 10th. Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Finally, Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.20.
View Our Latest Research Report on TLSI
TriSalus Life Sciences Company Profile
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Featured Articles
- Five stocks we like better than TriSalus Life Sciences
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
